Danaparoid for cardiopulmonary bypass in patients with previous heparin- induced thrombocytopenia

Shmuel Gillis, Gideon Merin, Doron Zahger, Maher Deeb, Benjamin Drenger, Esti Hyam, Amiram Eldor

    Research output: Contribution to journalArticlepeer-review

    23 Scopus citations

    Abstract

    Anticoagulation for cardiopulmonary bypass in patients with heparin- induced thrombocytopenia requires the use of other anticoagulants. We report a case in whom this was achieved using the heparinoid danaparoid (Orgaran). Based on our experience and a review of the literature, we provide guidelines for managing these rare patients. A danaparoid dose substantially lower than that recommended by the manufacturer may minimize bleeding complications.

    Original languageEnglish
    Pages (from-to)657-659
    Number of pages3
    JournalBritish Journal of Haematology
    Volume98
    Issue number3
    DOIs
    StatePublished - 1 Jan 1997

    Keywords

    • Cardiopulmonary bypass
    • Danaparoid
    • Heparin
    • Thrombocytopenia

    ASJC Scopus subject areas

    • Hematology

    Fingerprint

    Dive into the research topics of 'Danaparoid for cardiopulmonary bypass in patients with previous heparin- induced thrombocytopenia'. Together they form a unique fingerprint.

    Cite this